Bristol-Myers Squibb (BMY) Tops Q2 EPS by 17c; Boosts FY15 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Bristol-Myers Squibb Reports Second Quarter Financial Results
July 23, 2015 7:30 AM EDTIncreases Revenues 7% to $4.2 Billion Posts Second Quarter GAAP Loss Per Share of $0.08 and Non-GAAP EPS of $0.53 Achieves Important Regulatory and Clinical Milestones for Opdivo (nivolumab) Approvals in Europe for Metastatic Melanoma and Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Validation in Europe of Applications for Opdivo in Non-Squamous NSCLC and in Combination with Yervoy for Metastatic Melanoma Early Stop of CheckMate -025, a Phase 3 Study Evaluating in Patients with Renal Cell Carcinoma, After... More
